Sign In
Buy GNPX
$0.720
-0.0153 (-2.08%)
At Close: Jun 03, 2026
Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
09:29am, Wednesday, 04'th Sep 2024
Intends to Create Two Distinct Businesses, Re-Focusing Genprex on its Oncology Clinical Development Program New Subsidiary to Focus on Developing Novel Gene Therapy for Diabetes AUSTIN, Texas , Sept.
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
08:15am, Tuesday, 03'rd Sep 2024
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 3, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stag
Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
09:30am, Thursday, 15'th Aug 2024
Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes Video Highlights Recent Oncology Clinical Development Program Updates AUSTIN, Texas , Aug. 15, 2024 /PRNewswire/ --
Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer
09:25am, Wednesday, 14'th Aug 2024
Demonstrates Prolonged Progression Free Survival of Two Patients in Acclaim-1 and Partial Remission from Maintenance Therapy in Acclaim-3 Re-focuses Oncology Clinical Development Program and Advances
Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
08:31am, Tuesday, 13'th Aug 2024
Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors AUSTIN, Texas , Aug. 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "C
Genprex to Present at the August Sidoti Microcap Conference
08:30am, Thursday, 08'th Aug 2024
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Aug. 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update
08:31am, Thursday, 27'th Jun 2024
Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex
Genprex to Present at the 2024 BIO International Convention
08:31am, Thursday, 30'th May 2024
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage
Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations AUSTIN, Texas , May 14, 2024 /PRNewswire/ -- Genprex
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors
08:31am, Monday, 13'th May 2024
Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDA
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
06:08pm, Wednesday, 08'th May 2024
Ryan Confer Appointed Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences
08:31am, Wednesday, 01'st May 2024
AUSTIN, Texas , May. 1, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients
Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer Treatments REQORSA Has Anti-Tumor Mechanisms and Ability to Trigger Canc
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
10:01am, Thursday, 04'th Apr 2024
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices Acclaim-3 Study Supported by FDA Orphan Drug and Fas
